Patents by Inventor Jack Bikker

Jack Bikker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Single domain binding molecule
    Patent number: 11692025
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: July 4, 2023
    Assignee: ELASMOGEN LIMITED
    Inventors: Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • SINGLE DOMAIN BINDING MOLECULE
    Publication number: 20210332116
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Application
    Filed: May 17, 2021
    Publication date: October 28, 2021
    Inventors: Caroline BARELLE, Mischa Roland MULLER, Valarie CALABRO, Jack BIKKER, John STEVEN, Lioudmila TCHISTIAKOVA, Oleg KOVALENKO, Andrea OLLAND
  • Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
    Patent number: 11147852
    Abstract: The present invention is directed to antibodies, and antigen-binding portions thereof, engineered to introduce amino acids for site-specific conjugation. The invention relates to engineered antibody constant region (Fc, C?, C?, and C?) polypeptides, and portions thereof, and antibodies comprising the polypeptides. Further, the invention relates to Fc fusion proteins comprising an engineered Fc region. The invention also relates to methods and uses of the engineered antibodies and portions for, among other things, production of antibody-drug conjugate therapeutics.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: October 19, 2021
    Assignee: Pfizer Inc.
    Inventors: Kimberly Marquette, Eric Bennett, Lioudmila Tchistiakova, L. Nathan Tumey, Jack Bikker, Valerie Calabro, Edmund Graziani
  • Single domain binding molecule
    Patent number: 11034756
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: June 15, 2021
    Assignee: ELASMOGEN LIMITED
    Inventors: Caroline Barelle, Mischa Roland Muller, Valarie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • SINGLE DOMAIN BINDING MOLECULE
    Publication number: 20190194307
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Application
    Filed: March 8, 2019
    Publication date: June 27, 2019
    Inventors: Caroline BARELLE, Mischa Roland MULLER, Valarie CALABRO, Jack BIKKER, John STEVEN, Lioudmila TCHISTIAKOVA, Oleg KOVALENKO, Andrea OLLAND
  • Single domain binding molecule
    Patent number: 10287341
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: May 14, 2019
    Assignee: The University Court of the University of Aberdeen
    Inventors: Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • SINGLE DOMAIN BINDING MOLECULE
    Publication number: 20170096475
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Application
    Filed: September 22, 2016
    Publication date: April 6, 2017
    Applicant: The University Court of the University of Aberdeen
    Inventors: Caroline BARELLE, Mischa Roland MULLER, Valerie CALABRO, Jack BIKKER, John STEVEN, Lioudmila TCHISTIAKOVA, Oleg KOVALENKO, Andrea OLLAND
  • Single domain binding molecule
    Patent number: 9475870
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: October 25, 2016
    Assignee: The University Court of the University of Aberdeen
    Inventors: Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • SINGLE DOMAIN BINDING MOLECULE
    Publication number: 20160137726
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Application
    Filed: January 25, 2016
    Publication date: May 19, 2016
    Inventors: Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • Engineered Antibody Constant Regions for Site-Specific Conjugation and Methods and Uses Therefor
    Publication number: 20160008485
    Abstract: The present invention is directed to antibodies, and antigen-binding portions thereof, engineered to introduce amino acids for site-specific conjugation. The invention relates to engineered antibody constant region (Fc, C?, C?, and C?) polypeptides, and portions thereof, and antibodies comprising the polypeptides. Further, the invention relates to Fc fusion proteins comprising an engineered Fc region. The invention also relates to methods and uses of the engineered antibodies and portions for, among other things, production of antibody-drug conjugate therapeutics.
    Type: Application
    Filed: December 19, 2012
    Publication date: January 14, 2016
    Inventors: Kimberly Marquette, Eric Bennett, Lioudmila Tchistiakova, L. Nathan Tumey, Jack Bikker, Valerie Calabro, Edmund Graziani
  • SINGLE DOMAIN BINDING MOLECULE
    Publication number: 20130302250
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Application
    Filed: May 7, 2013
    Publication date: November 14, 2013
    Inventors: Caroline BARELLE, Mischa MULLER, Valerie CALABRO, Jack BIKKER, John STEVEN, Lioudmila TCHISTIAKOVA, Oleg KOVALENKO, Andrea OLLAND
  • Bicyclic inhibitors of protein farnesyl transferase
    Patent number: 6528535
    Abstract: The present invention provide compounds of Formula I The present invention also provides a method of treating cancer and treating or preventing restenosis or atherosclerosis. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula I.
    Type: Grant
    Filed: July 23, 2001
    Date of Patent: March 4, 2003
    Assignee: Warner-Lambert Company
    Inventors: Jack Bikker, Ellen Myra Dobrusin, Annette Marian Doherty, Matthew Drowns, James Stanley Kaltenbronn, Juergen Kleinschroth, Dennis Joseph McNamara, John Quin, III, Joseph Thomas Repine, Marcin Stasiak
  • Bicyclic inhibitors of protein farnesyl transferase
    Publication number: 20020006936
    Abstract: The present invention provides compounds of Formula I 1
    Type: Application
    Filed: July 23, 2001
    Publication date: January 17, 2002
    Inventors: Jack Bikker, Ellen Myra Dobrusin, Annette Marian Doherty, Matthew Drowns, James Stanley Kaltenbronn, Juergen Kleinschroth, Dennis Joseph McNamara, John Quin, Joseph Thomas Repine, Marcin Stasiak
  • Bicyclic inhibitors of protein farnesyl transferase
    Patent number: 6265422
    Abstract: The present invention provides compounds of Formula I The present invention also provides a method of treating cancer and treating or preventing restenosis or atherosclerosis. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula I.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: July 24, 2001
    Assignee: Warner-Lambert Company
    Inventors: Jack Bikker, Ellen Myra Dobrusin, Annette Marian Doherty, Matthew Drowns, James Stanley Kaltenbronn, Juergen Kleinschroth, Dennis Joseph McNamara, John Quin, III, Joseph Thomas Repine, Marcin Stasiak
  • Bicyclic inhibitors of protein farnesyl transferase
    Patent number: 6133303
    Abstract: The present invention provides compounds of Formula (I). The present invention also provides a method of treating cancer and treating or preventing restenosis or atherosclerosis. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula (I).
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: October 17, 2000
    Assignee: Warner-Lambert Company
    Inventors: Jack Bikker, Ellen Myra Dobrusin, Annette Marian Doherty, Matthew Drowns, James Stanley Kaltenbronn, Juergen Kleinschroth, Dennis Joseph McNamara, John Quin, III, Joseph Thomas Repine, Marcin Stasiak